Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02404220.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationGilead

• Primary IDGS-US-339-1560
• Secondary IDsNCI-2015-01374, 2015-002768-18
• ClinicalTrials.gov IDNCT02404220